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Increasing evidence suggests that platelets play a predominant role in colon and breast
cancer metastasis, but the underlying molecular mechanisms remain elusive. Glycoprotein
VI (GPVI) is a platelet-specific receptor for collagen and fibrin that triggers platelet acti-
vation through immunoreceptor tyrosine-based activation motif (ITAM) signaling and
thereby regulates diverse functions, including platelet adhesion, aggregation, and pro-
coagulant activity. GPVI has been proposed as a safe antithrombotic target, because its
inhibition is protective in models of arterial thrombosis, with only minor effects on he-
mostasis. In this study, the genetic deficiency of platelet GPVI in mice decreased exper-
imental and spontaneous metastasis of colon and breast cancer cells. Similar results were
obtained with mice lacking the spleen-tyrosine kinase Syk in platelets, an essential com-
ponent of the ITAM-signaling cascade. In vitro and in vivo analyses supported that mouse,
as well as human GPVI, had platelet adhesion to colon and breast cancer cells. Using a
CRISPR/Cas9-based gene knockout approach, we identified galectin-3 as the major counterreceptor of GPVI on tumor
cells. In vivo studies demonstrated that the interplay between platelet GPVI and tumor cell–expressed galectin-3 uses
ITAM-signaling components in platelets and favors the extravasation of tumor cells. Finally, we showed that JAQ1
F(abʹ)2-mediated inhibition of GPVI efficiently impairs platelet–tumor cell interaction and tumor metastasis. Our study
revealed a new mechanism by which platelets promote the metastasis of colon and breast cancer cells and suggests
that GPVI represents a promising target for antimetastatic therapies. (Blood. 2020;135(14):1146-1160)
Introduction
Metastasis is the leading cause of cancer-related death and
represents a major challenge in patient care.1 Although many
anticancer therapies have been developed, the prognosis re-
mains unfavorable once metastatic dissemination has occurred.2
Tumor metastasis develops in sequential steps: detachment of
tumor cells from the primary tumor and intravasation into the
blood or lymphatic circulation, transport within the bloodstream,
extravasation, and colonization of distant sites and growth of
metastases.1 Although some mechanisms reflect tumor cell–
autonomous processes, most require the interaction of tumor
cells with blood cells, including myeloid cells and platelets.1,3,4
The interaction of tumor cells with platelets enhances their
survival in the bloodstream and facilitates tumor metastasis.5,6
Platelets shield tumor cells against mechanical destruction by
hemodynamic shear stress and lysis by natural killer cells.7
Activated platelets can release cytokines, growth factors, and
secondary mediators, thereby enhancing tumor cell invasive-
ness, epithelial–mesenchymal transition, extravasation, and
promotion of angiogenesis and vascular remodelling.3,8-11 The
presence of tumor cell–activated platelets in the bloodstream
can predispose cancer patients to thrombotic events, further
increasing tumor cell malignancy.4,12 Consistently, thrombocy-
tosis, tumor cell–induced platelet aggregation, and high plasma
fibrinogen concentration and D-dimer levels are associated with
a poor prognosis of solid cancers, such as breast, colon, and
ovarian cancers, implicating the contribution of platelets in the
progression of the disease.4,13-16 It has been shown that platelet-
expressed membrane receptors, such as P-selectin, integrin
aIIbb3, integrin a6b1, and C-type lectin-like receptor-2, con-
tribute to the interaction between platelets and tumor cells,
endothelial cells, and fibrin, thereby influencing cancer pro-
gression and metastasis.5,17-21
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Glycoprotein (GP) VI (GPVI) is a receptor for collagen, laminin,
and fibrin, which regulate multiple platelet functions, such as
adhesion, aggregation, and procoagulant activity.22-27 After li-
gand binding, GPVI forms receptor clusters on the platelet
surface. Src kinase–dependent tyrosine phosphorylation of the
immunoreceptor tyrosine-based activation motif (ITAM) of the
GPVI-associated FcRg chain induces a signaling pathway in-
volving Src and Syk tyrosine kinases, which further phosphor-
ylate and activate the linker of activated T-cell signalosome






































































































































































Figure 1. Lack of platelet GPVI inhibits tumor metastasis. (A) Schematic of a lung colonization assay after IV injection of MC38 colon (B,D) or AT-3 breast (C,E) cancer cells in
WT and Gp62/2 mice. (B,C) Representative photographs (top) and hematoxylin-eosin–stained sections (bottom) obtained from the lungs of MC38 and AT-3–injected WT and
Gp62/2 mice. (B,C) Dashed black circles and arrows indicate metastatic nodules. The bar represents 200 mm. (D,E) Bar graphs representing the number of lung metastases in
MC38 (D)- and AT-3 (E)–injected WT and Gp62/2 mice. Mean 6 standard deviation (SD); n 5 5 (D) and n 5 7 (E) mice per group. ***P , .001, by unpaired Student t test. (F,I)
Schematic of mouse heterotopic and orthotopicmetastasis assays.MC38 (F-H) and AT-3 (I-K) tumor cells were injected subcutaneously or into the fourthmammary fat pad ofWT
andGp62/2 mice, and the volume of subcutaneous (G) or mammary (J) tumors and the number of lung metastases was determined. (G,J) Kinetic of primary tumor growth inWT
and Gp62/2 mice. Mean6 SD; n 5 5 (G) and n 5 8 (J) per group. (H,K) The number of spontaneous lung metastases in MC38 (H)- and AT-3 (K)–injected WT and Gp62/2 mice.
Mean 6 SD; n 5 6 (H) and n 5 8 (K) mice per group. *P , .05; **P , .01, by Mann-Whitney test.










































































































































Figure 2. Genetic deficiency or antibody-mediated blockade of GPVI impairs platelet–tumor cell interaction. Platelet adhesion to tumor cells was quantified based on the
fluorescence detection of anti-GPIX–labeled platelets, as described in “Materials and methods.” (A-B) WashedWT or Gp62/2 mouse platelets (Plts) were allowed to adhere to
MC38 colon and AT-3 breast cancer cells. The bar represents 20 mm. (C) Similar experiments were performed withWTmouse platelets treated with JAQ1 F(abʹ)2 or an irrelevant
control F(abʹ)2 antibody. (D) Representative SEM images of WT and Gp62/2 mouse platelets adhering to MC38 tumors cells. Washed mouse platelets were mixed with MC38
colon cancer cells (100 platelets/cell), incubated for 1 hour at 37°C, and then analyzed by SEM. The bar represents 8 mm. Arrows indicate platelets (magenta) and tumor cells
(black). (E-F) Washed human platelets were isolated from patients carrying the heterozygous (GP61/2) or homozygous (GP62/2) mutation in theGP6 gene or from healthy donors
and coincubated with human HT29 colon and MDA-MB-231 breast cancer cells. Shown are representative images of GP61/2 and GP62/2 platelets adhering to HT29 and MDA-
MB-231 cells. The bar represents 20mm. (B-C,F) Quantification of the fluorescence signal corresponding to the number ofmouse (B-C) and human (F) platelets adhering to tumor
cells. (B-C) Mean6 standard deviation (SD); n5 4 mice per group; *P, .05, by Mann-Whitney test. (F) Mean6 SD; Ctrl (healthy donor), n5 3;GP61/2, n5 2; andGP62/2, n5 3.
*P , .05; **P , .01, by unpaired Student t test. (G,H) Experimental design: thrombocytopenic mice were transfused with Cy3-conjugated anti-GPIX-labeled WT or Gp62/2
platelets (red) and CFSE-labeledMC38 tumor cells (green). One hour after injection, mice were euthanized, the lungs were collected, and the colocalization of MC38 tumor cells
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potentially safe antithrombotic target based on the observations
that its blockade reduces arterial thrombosis without impairing
hemostasis.29-32 Besides its central role in thrombosis, GPVI is
involved in the maintenance of vascular integrity under in-
flammatory conditions.28,33-37 The role of this ITAM-containing
receptor in tumor metastasis has not been well investigated, and
only a few studies are currently available that assessed this
process. In experimental metastatic approaches, GPVI defi-
ciency in mice leads to a decreased number of metastatic foci
of B16-F10 and Lewis lung carcinoma (LLC) cells.38 In addition,
we recently showed that functional inhibition of GPVI induces
bleeding and tumor hemorrhage, thereby increasing the intra-
tumoral efficacy of chemotherapeutic drugs within primary tu-
mors.39 However, molecular mechanisms underlying the role of
GPVI in tumor metastasis has not been elucidated.
In our study, we showed that platelets promote metastasis of
colon and breast cancer cells through an interaction between
platelet GPVI and its counterreceptor galectin-3. Our findings
demonstrated that platelet GPVI and galectin-3 expressed on
tumor cells may represent a new therapeutic target or axis for
combating tumor metastasis.
Details of materials and methods are described in the supple-
mental Methods, available on the Blood Web site.
Materials and methods
Animals
C57BL/6 and BALB/c1 mice were obtained from Janvier (Le
Genest-Saint-Isle, France).Gp62/2, Unc13d2/2, and Sykfl/fl, Pf4-cre1/2
(Syk2/2) mice lacking Syk kinase inmegakaryocyte/platelet lineage
and their control littermates Sykfl/fl, Pf4-cre2/2 (Syk1/1) have been
described previously.40-42 Lgals32/2 mice were purchased from
Jackson Laboratories and crossed with Gp62/2 mice. All the in-
dicated genetically modified mouse strains were established on a
C57BL/6 background. Animal procedures described in this study
were approved by the Regional Administration of Unterfranken
(Lower District), Würzburg, Germany. The experiments were per-
formed in accordance with relevant guidelines and regulations.
Experimental and spontaneous models of
tumor metastasis
MC38 and MC38-CEA colon and AT3 and E0771 breast cancer
cell lines are syngeneic to C57BL/6 and 4T1 breast cancer lines,
respectively, on a BALB/c1 background,. To study experimental
metastasis, we injected 1 3 106 MC38 or MC38-CEA; 5 3 105
E0771 or AT-3; or 3 3 105 4T1 parental, control, or Lgals3-
knockout cells into the lateral tail vein. Mice were euthanized
at day 15 after injection, and the number of metastases was
determined by counting the metastatic foci on the lung surface.
To study spontaneous metastasis, we injected 5 3 105 MC38
or MC38-CEA colon or 3 3 105 AT-3 breast cancer cells sub-
cutaneously or into a mammary fat pad of 8-week-old male and
female virgin mice, respectively, and the animals were eutha-
nized at day 30 after injection. Tumor volumes were measured
with Vernier calipers and determined with the following
calculation: V5 (width)23 length/2. In some experiments, wild-
type (WT) mice were injected with 100 mg JAQ1 F(abʹ)2 or an
irrelevant control F(abʹ)2 antibody, 1 mg/kg acetylsalicylic acid
(ASA [aspirin]; Aspisol), or 4 mg/kg GPVI-Fc43 or were depleted
of neutrophils by using the 1A8 antibody (5 mg/kg; BD Bio-
sciences, Heidelberg, Germany).
Results
GPVI deficiency decreases metastasis of colon and
breast cancer cells
To directly test the hypothesis that GPVI has a role in the me-
tastasis of colon and breast cancer cells, we injected MC38 colon
cancer cells and AT-3 breast cancer cells into the tail vein of
syngeneic WT and GPVI-deficient (Gp62/2) mice and determined
the extent of lungmetastasis after 15 days (Figure 1A-E). Although
both MC38 and AT-3 cell lines established pulmonary metastatic
foci, they were significantly decreased in Gp62/2 mice compared
with WT controls (Figure 1D-E; supplemental Figure 1A-B).
Models of spontaneous metastasis encompass early and late
stages of cancer progression, involving cell implantation, at
either a heterotopic or orthotopic site, to form a primary tumor
that may subsequently disseminate.44,45 The effect of GPVI
deficiency on spontaneous metastasis was determined by the
subcutaneous injection of MC38 cells (Figure 1F), representing a
heterotopic colon cancer model. In another set of experiments,
AT-3 cells were injected into the mammary fat pad (orthotopic
breast cancer model; Figure 1I), and tumor size was evaluated
every 5 days. We found that both cell types established primary
tumors with similar kinetics in Gp62/2 mice compared with the
WT controls (Figure 1G, J). In contrast, the number of sponta-
neously formed lung metastases was reduced inGp62/2 mice by
2.5- and 1.8-fold, respectively, compared with the WT controls
(Figure 1H, K; supplemental Figure 1C-D).
GPVI contributes to platelet–tumor cell interaction
The first hours of a tumor cell in the bloodstream are critical for its
survival and successful metastasis, and platelets are the first cells
to interact with circulating tumor cells.4,6 To evaluate whether
GPVI is involved in platelet–tumor cell interaction, platelets were
allowed to adhere to tumor cells in vitro under static conditions.
Gp62/2 mouse platelets showed reduced recruitment to colon
(MC38), breast cancer (AT-3), and LLC cells compared with WT
control platelets (Figure 2A-B; supplemental Figure 2A). Similar
results were obtained when GPVI function was blocked in WT
platelets by adding F(ab9)2 fragments of the JAQ1 antibody
(Figure 2C; supplemental Figure 2B). This interaction was also
visualized in cell suspension by using scanning electron mi-
croscopy (SEM), confirming that adhesion of GPVI-deficient
platelets to tumor cells was strongly inhibited (Figure 2D).
Previously, Matus et al46 and Onselaer et al47 described families
with a loss-of-function mutation of GPVI and heterozygous rel-
atives (hGP61/2). We investigated the adhesion efficiency of
control, hGP61/2, and hGP62/2 human platelets to human co-
lorectal HT29 and breast MDA-MB-231 cancer cells and found
Figure 2 (continued) with platelets was determined by confocal microscopy. Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI; blue). The bar represents 20 mm.
(H) Quantification of the number of tumor cells surrounded or not by platelets. Mean6 SD, n5 4 mice per group, tumor cells (TC) without PltsWT vsGp62/2, *P, .05; TC with
Plts WT vs Gp62/2; **P , .01, by 2-way analysis of variance with Bonferroni’s multiple-comparison test.







































































































































































































































Figure 3. Galectin-3 expressed on tumor cells supports GPVI-dependent platelet adhesion. (A) Prediction of binding affinity between galectin-3 (red) and GPVI (blue).
Graphs correspond to DGbind 5 25.91 kcal/mol and KD 5 44.89 mM, respectively. Potential of mean force (PMF) values were extracted by the weighted histogram analysis
method, which yields the binding free energy (DGbind) for the binding and unbinding processes. The DGbind value was calculated as the difference between the highest and
lowest values of the PMF curve. TheKD of the protein–protein complexwas calculated from theDGbind value according to the following equation: KD5 exp(DGbind/R × T), where R
(gas constant) is 1.98 cal(mol×K)21 and T (room temperature) is 298.15 Kelvins (K). The Boltzmann (sigmoidal) nonlinear fitting [R25 0.85; RMSE (rootmean square error)5 0.67; RSS
(residual sum of squares)5 88.31] of the data set is shown to assess the PMF elevation pattern with the increase of reaction coordinate (j), using the scaled Levenberg-Marquardt
algorithm with tolerance 5 0.0001. (B-C) Knockout of the galectin-3 gene (Lgals3 KO) expression in MC38 and AT-3 cells. (B) Galectin-3 mRNA expression was determined by
quantitative reverse transcription polymerase chain reaction and normalized with a messenger RNA level of glyceraldehyde-3-phosphate dehydrogenase. Data are presented
as the mean 6 standard deviation (SD) of 4 separate cell culture experiments; *P , .05, by Mann-Whitney test. (C) Representative immunofluorescence images of galectin-3
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that hGP62/2 platelet adhesion to the tumor cells was markedly
reduced (Figure 2E-F).
Next, platelet interaction with tumor cells was determined
in vivo. Carboxyfluorescein diacetate succinimidyl ester (CFSE)–
labeled tumor cells and platelets labeled with Cy3-conjugated
anti-GPIX antibody derivative were injected into the tail vein of
thrombocytopenic mice, and the lungs were collected after 1 hour
(Figure 2G). Immunofluorescence confocal microscopy of lung
sections revealed that the number of tumor cells covered by
platelets was markedly reduced in mice transfused with Gp62/2
platelets compared with those transfused with WT platelets
(Figure 2H), suggesting an essential role of GPVI in platelet–tumor
cell interaction.
Galectin-3 binding to GPVI supports
platelet–tumor cell interaction
Galectins induce platelet adhesion and aggregation,48 and
upregulation of galectins is a hallmark of various malignancies.49,50
Galectin-3 contains a collagen-like domain and is highly expressed
by various cancer cells,51,52 including cell lines used for our
studies (supplemental Figure 3). Therefore, we hypothesized
that galectin-3 initiates platelet–tumor cell binding through
interactions with the collagen-binding site of GPVI. First, we
modeled the GPVI–galectin-3 binding using already available
crystal structures53,54 and bioinformatics tools55,56 and found
that the structure of galectin-3 is preferentially shifted toward
the B chain of GPVI by covering a larger interaction area on the
surface of protein, including more interaction residues, com-
pared with the A chain (supplemental Figure 4; supplemental
Table 1). According to the umbrella sampling methodology,57
binding affinity was estimated as DGbind 525.91 kcal/mol and
dissociation constant (KD) 5 44.89 mM (Figure 3A) and com-
pared with the binding affinity between GPVI and collagen
types I (DGbind  26.91 kcal/mol and KD 5 8.1 6 1.2 mM) and
III (DGbind  26.6 kcal/mol and KD 5 13.8 6 2.5 mM) from a
previous study.58
To confirm our bioinformatics result experimentally, we deleted
galectin-3 expression in colon (MC38) and breast cancer (AT-3,
4T1, and E0771) cell lines using a CRISPR/Cas9 strategy (Figure
3B-C; supplemental Figure 5). Interestingly, the interaction of
WT platelets with galectin-3–deficient MC38, AT-3, 4T1, and
E0771 cancer cells was markedly reduced compared with the
respective control tumor cells (Figure 3D; supplemental Figure 5),
indicating a crucial role of galectin-3 in mediating platelet–tumor
cell interactions. Of note, adhesion of WT platelets to galectin-
3–deficient cancer cells was similar to the adhesion level ofGp62/2
platelets to galectin-3–expressing cancer cells. Furthermore, no
additive inhibitory effect was observed when Gp62/2 platelets
were added to galectin-3–deficient cancer cells (Figure 3D).
Similar results were obtained when GPVI function was blocked in
WT platelets by adding F(abʹ)2 fragments of the JAQ1 antibody
(Figure 3E). Next, WT and Gp62/2 platelets were allowed to ad-
here to a recombinant galectin-3 protein under static conditions.
We found that Gp62/2 platelet adhesion to the galectin-3–coated
surface decreased significantly compared with that of the WT
controls (Figure 3F-G). A similar inhibition was obtained using
GPVI-depleted platelets isolated from JAQ1-IgG–injected mice32
(Figure 3F-G) or using GPVI-deficient human platelets (Figure
3H-I). Of note, GPVI deficiency did not reduce platelet adhesion
on recombinant galectin-1, which has a structure similar to galectin-3
but lacks the collagen-like domain (supplemental Figure 6). Next,
weused fluorescentmicrospheres conjugated to a soluble dimeric
form of GPVI (GPVI-Fc)43 in static adhesion assays and found a
specific interaction with galectin-3, but not with galectin-1 (Figure
3H). Similar results were obtainedby enzyme-linked immunosorbent
assay (Figure 3J), indicating that the collagen-like domain of
galectin-3 is involved in the interaction with GPVI.
GPVI–galectin-3 interaction regulates lung
metastasis
To address the functional consequences of GPVI–galectin-3
interaction for tumor metastasis, MC38 control or galectin-
3–deficient cells were injected subcutaneously into WT and
Gp62/2 mice. After 30 days, volumes of primary tumors were
similar between groups, indicating that neither platelet GPVI nor
tumor cell–resident galectin-3 is critical for primary tumor growth
(Figure 4A). In contrast, in WT mice, spontaneous metastasis of
galectin-3–deficient MC38 cells was decreased by 2.5-fold,
compared with that of control cells (Figure 4B). Genetic ablation
of galectin-3 in MC38 (Figure 4C) and AT-3 (Figure 4D) cancer
cells caused a similar impairment of lung colonization after in-
oculation via the tail vein. Interestingly, the combined deficiency
of GPVI and galectin-3 on platelets and tumor cells, respectively,
did not further decrease the number of spontaneous (Figure 4B)
or experimental (Figure 4C-D) lungmetastases. Galectin-3 is also
expressed by stromal, endothelial, and immune cells.59,60 To test
whether other galectin-31 cells may account for the observed
phenotype, galectin-3–deficient mice (Lgals32/2) or Gp62/2
Lgals32/2 double-knockout mice were injected with tumor cells,
and lung colonization was assessed after 15 days (Figure 4E).
Figure 3 (continued) (Lgals3 KO) knockout MC38 and AT-3 cells or cells expressing galectin-3 gene (Ctrl: control), with an anti-galectin-3 antibody (red). Nuclei were stained with 49,6-
diamidino-2-phenylindole (DAPI; blue). The bar represents 20 mm. (D-E) Quantification of the fluorescence signal corresponding to the amount of WT (D-E) and Gp62/2 (D)
mouse platelets adhering to (D-E) MC38 and AT-3 Ctrl and Lgals3 KO cancer cells. (D) Data are presented as themean6 SD; n5 3 mice per group. MC38 Ctrl/WT platelets (plts;
3.6076 0.6198); MC38 Ctrl/Gp62/2 plts (1.5936 0.2774); MC38 Lgals3 KO/WT plts (1.66 0.2402); and MC38 Lgals3 KO/Gp62/2 plts (1.423 6 0.1665). AT-3 Ctrl/WT plts (5.37 6
0.3005); AT-3 Ctrl/Gp62/2 plts (1.8976 0.4944); AT-3 Lgals3 KO/WTplts (1.8176 0.586); and AT-3 Lgals3 KO/Gp62/2 plts (1.6836 0.486). ***P, .001; ****P, .0001, 1-way analysis
of variance (ANOVA) followed by Tukey’s post hoc test. (E) Similar experiments were performed with WT platelets in the absence or presence of JAQ1 F(abʹ)2 or an irrelevant
control F(abʹ)2 antibody. Data are presented as the mean6 SD; n5 3 mice per group. MC38 Ctrl/Ctrl F(abʹ)2 plts (5.0176 0.2055); MC38 Ctrl/JAQ1 F(abʹ)2 plts (2.4376 0.493);
MC38 Lgals3 KO/Ctrl F(abʹ)2 plts (2.7576 0.2139); and MC38 Lgals3 KO/JAQ1 F(abʹ)2 plts (2.2736 0.4366). AT-3 Ctrl/Ctrl F(abʹ)2 plts (5.3136 0.5326); AT-3 Ctrl/JAQ1 F(abʹ)2 plts
(2.38 6 1.057); AT-3 Lgals3 KO/Ctrl F(abʹ)2 plts (1.967 6 0.2259); and AT-3 Lgals3 KO/JAQ1 F(abʹ)2 plts (2.01 6 0.1825). **P , .01; ***P , .001; ****P , .0001, by 1-way ANOVA,
followed by Tukey’s post hoc test. (F,H) Representative immunofluorescencemicroscopy images ofmouse (WT andGp62/2) (F) and human (H; top; Ctrl, healthy subject; hGP61/2,
human patient with heterozygous mutation; and hGP62/2, human patient with homozygous mutation) platelets adhering to recombinant galectin-3 under static conditions. The
bar represents 20 mm. (H, bottom). Representative immunofluorescence images of GPVI-Fc–conjugated fluorescent microspheres adhering on galectin-1–, galectin-3– and
collagen I–coated surfaces. (G,I) Quantification of adherent mouse (G) and human (I) platelets under static conditions on galectin-3. (G) Mean6 SD; n5 4 mice per group;
*P, .05, by Mann-Whitney test. (I) Mean6 SD. Ctrl, n5 5; hGP61/2, n5 2; and hGP62/2, n5 3. (J) Binding of dimeric GPVI to galectin-3. GPVI–Fc-Alexa-488 was added to
microwells coated with galectin-1, galectin-3, collagen I, or bovine serum albumin (BSA). Protein binding was assessed by measuring the fluorescence intensity (FI) at 488 nm.
Data are presented as the mean 6 SD of 4 separate experiments. *P , .05; **P , .01, by 1-way ANOVA, followed by Tukey’s post hoc test.
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Galectin-3 deficiency in host cells did not affect metastasis,
compared with that of the control cells (Figure 4E). Altogether,
these results indicate that GPVI–galectin-3 interactions regulate
tumor metastasis, but not primary tumor growth.
GPVI–galectin-3 interaction promotes tumor
cell–induced platelet activation, degranulation,
and transendothelial cell migration
Next, we evaluated the role of the GPVI downstream effector
Syk and Src kinases in the process of platelet spreading on
a galectin-3–coated surface. Whereas control platelets rapidly
adhered, formed filopodia, and spread on galectin-3, this pro-
cess was strongly attenuated in the presence of 10 mMof the Syk
inhibitor Bay 61-3606 (Figure 5A,D) or the Src inhibitor PP1
(Figure 5B,D). Syk-deficient platelets also showed similar
spreading defects on galectin-3 (Figure 5C-D). This was further
confirmed by the reduced adenosine triphosphate (ATP) release
of galectin-3–adherent Syk2/2 platelets compared with Syk1/1
platelets (Figure 5E).We also found that calcium (Ca21) signaling,
P-selectin exposure (supplemental Figures 7 and 8), and ATP
release from Gp62/2 platelets were reduced compared with WT
platelets when coincubated with tumor cells (Figure 5F) and that
the levels of released ATP were dependent on galectin-3 ex-
pression by tumor cells (Figure 5F).
It has been shown that tumor cell–induced platelet degranula-
tion and ATP release stimulate transendothelial migration of
tumor cells, thereby enhancing their metastatic potential.3,9,17
Therefore, we hypothesized that GPVI–galectin-3 interactions
regulate the transendothelial migration of tumor cells, which
requires both endothelial cell tight junction (TJ) disruption and
tumor cell migration. To test this directly, WT or GPVI-deficient
platelets were incubated with control or galectin-3 knockout
tumor cells, and cell-free supernatants were used to treat bEnd.3
endothelial cells. The function of TJs on the cell surface was
evaluated with immunofluorescence staining of vascular endo-
thelial (VE)-cadherin, as previously described.61 Interestingly, VE-
cadherin staining was diffuse, and gaps between the cells were
apparent, indicative of vascular permeability, when endothelial
cells were treated with supernatants derived from cocultures
of WT platelets with MC38 cells. In contrast, normal TJs were
observed in cells treated with supernatants from Gp62/2
platelets and control MC38 cells or WT platelets incubated with
galectin-3–deficient MC38 tumor cells (Figure 5G; supplemental
Figure 9). Of note, incubation of endothelial cells with the ATP
analog, ATPgS, was sufficient to induce the dissociation of TJs,
whereas the addition of the ATP-hydrolyzing enzyme apyrase
abolished this process (Figure 5H; supplemental Figure 9). Next,
control and galectin-3–knockout tumor cells were allowed to
migrate through bEnd.3 mouse endothelial cell–coated trans-
wells, alone or in the presence of washed WT or Gp62/2
platelets. We found that the addition of WT platelets enhanced
transendothelial migration of MC38 and AT-3 tumor cells by 2.7-
and 2.5-fold, compared with controls without platelets (Figure
5H-I). In contrast, both Gp62/2 platelets incubated with control
tumor cells orWT platelets with galectin-3–knockout tumor cells
failed to enhance transendothelial migration (Figure 5H-I).
Similar results were obtained with platelets isolated from
Munc13-4 mice (Unc13d2/2),41 which do not release the major
ATP store from their platelet-dense granules (Figure 5H-I). Al-
together, these results suggest that GPVI–galectin-3 interactions
promote transendothelial migration of tumor cells in vitro and
that ATP release from platelet-dense granules stimulate this
process.
GPVI–galectin-3 interaction promotes tumor cell
extravasation and metastasis
To explore whether GPVI and its downstream signaling also have
an impact on tumor cell transmigration in vivo, Gp62/2 and WT
mice received CFSE-labeled tumor cells IV and were then an-
alyzed at different time points. The number of tumor cells
present in the lungs was comparable between the 2 groups
6 hours after injection, but a smaller proportion of cells was
localized in the extravascular compartment in Gp62/2 mice
compared with the controls (Figure 6A-B). We also found that
Syk2/2 platelets failed to enhance tumor cell extravasation
(Figure 6C-D). Consistently, spontaneous (Figure 6E) and ex-
perimental (Figure 6F) metastasis of MC38 colon (Figure 6E-F)
and AT-3 breast (Figure 6F) cancer cells were decreased in mice
with Syk-deficient platelets, suggesting that ITAM-dependent
platelet activation triggered by GPVI–galectin-3 interaction is
essential for tumor metastasis.
Pharmacological blockade of GPVI reduces
tumor metastasis
To address the antimetastatic effects of pharmacologically tar-
geting GPVI, C57BL/6 mice were treated with the GPVI-blocking
JAQ1 F(abʹ)2 or with an irrelevant IgG F(abʹ)2 control. This GPVI
blockade efficiently inhibited lung metastasis of both MC38
colon and AT-3 breast cancer cell lines (Figure 7A). Similar results
were obtained with the 4T1 breast cancer cell lung metastasis
model in syngeneic BALB/c1 mice (Figure 7B). Of note, JAQ1
F(abʹ)2 treatment did not exert any protective effect on tumor
metastasis when given at day 7 after injection of the tumor cells
(Figure 7C), suggesting that GPVI plays a role in the earlier steps
of tumor metastasis.
Discussion
In the present study, we demonstrated a key role of GPVI in
supporting platelet adhesion to tumor cells and identified
galectin-3 as a major GPVI ligand on tumor cells that induces
platelet activation to promote colon and breast cancer metastasis.
Galectin-3 is mainly located in the cytoplasm, but is also found in
the nucleus and on the cell surface and is also secreted into the
circulating blood.59,62 In addition, galectin-3 has been detected
on the surface of different cancer cell types and is also associated
with mucins, glycans, and integrins.62-67 Galectin-3 bears a
unique putative collagen-like domain, whereas the other
galectin isoforms lack this structure.52,62,68 To visualize the pu-
tative binding sites of galectin-3 on the protein surface of GPVI,
bioinformatics tools and crystal structures of galectin-3 and GPVI
were used. By using a free-energy calculation method,69 we
found that the binding affinity of GPVI to galectin-3 seems to be
close to type I or III collagen. Using different experimental
settings, we demonstrated that tumor-resident galectin-3 is
a binding partner of platelet GPVI and that this interaction in-
duces platelet activation, shape change, degranulation, and
ATP secretion. Platelet-released ATP has been shown to act on
the endothelial purinergic receptor P2Y2, thereby increasing
vascular permeability, which further enhances tumor cell ex-
travasation.9 In line with this report, our findings suggest that
galectin-3–GPVI–mediated platelet ATP release promotes tumor
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cell extravasation by inducing vascular permeability, thus strongly
facilitating metastasis formation in distant organs (Figure 7D).
It has been shown that downregulation of galectin-3 in osteo-
sarcoma, thyroid, and gastric cancer cells leads to decreased
tumor cell invasion and metastasis.70-72 In agreement with these
studies, our results also suggest a prometastatic function of colon
and breast cancer cell–derived galectin-3 in our immunocompetent
mouse models. Jain and collaborators38 described that GPVI
deficiency in mice results in decreased experimental metastasis
of B16F10 melanoma and LLC cells. Interestingly, galectin-3 is
detectable in both types of cancer cells,73 and LLC tumor cells
interact with platelets through GPVI.
Galectin-3 in human melanoma cell xenografts and experimen-






















































































































Figure 4. Galectin-3 on tumor cells mediates lung metastasis through platelet GPVI. Control (Ctrl) and galectin-3–deficient (Lgasl3 KO), MC38 and AT-3 tumor cells were
injected subcutaneously (A) or directly into the tail vein (C-E) of WT, Gp62/2 (B-E) and Lgals32/2 or Gp62/2Lgals32/2 (E) mice. Spontaneous (B) and experimental (C-E) lung
metastasis were determined 30 or 15 days after injection, respectively. Quantification of primary MC38 tumor volume (A) and metastases (B-E) in lungs ofWT, Gp62/2 (B-E) and
Lgals32/2 or Gp62/2Lgals32/2 (E) mice. Data are presented as the mean6 standard deviation (SD); n5 6 (A-C) and 5 (D-E) mice per group. *P, .05; **P, .01; ***P, .001;
****P , .0001, by 1-way analysis of variance followed by Tukey’s post hoc test. TC, tumor cells.












































































































































































































































Figure 5. Interaction between GPVI and galectin-3 promotes tumor cell–induced platelet activation, degranulation, and transendothelial migration. (A-C) Repre-
sentative SEM images of mouse platelets adhering to recombinant galectin-3.WashedWTmouse platelets were incubated for 10minutes with 10mmol/L of the Syk inhibitor Bay
61-3606 (A) and Src-kinase inhibitor PP1 and its nonfunctional analog PP3 (B) and was allowed to adhere to galectin-3–coated surfaces. (C) Similar experiments were performed
with Syk1/1 and Syk2/2mouse platelets. Themorphology of the adhering platelets was examined after 1 hour, and (D) the percentage of spread platelets was quantified for each
condition. The bar represents 20 mm.Mean6 standard deviation (SD) of n5 4 mice per group; *P, .05, by Mann-Whitney test. (E) Relative levels of ATP released from platelets
(Syk1/1 and Syk2/2) adhering to dalectin-3. Mean6 SD; n5 4 mice per group; *P, .05, by Mann-Whitney test. (F) Relative levels of ATP released fromWT andGp62/2 platelets
incubated with control MC38 (Ctrl) or Lgals3 KO tumor cells. Data are presented as the mean6 SD of 4 separate experiments. *P, .05, **P, .01, by 1-way analysis of variance
followed by Tukey’s post hoc test. (G) bEnd.3 mouse endothelial cells (ECs) incubated with supernatants derived from platelets (Plts) tumor cell (TC) cocultures (WT Plts1MC38
ctrl or Lgals3 KO TC) and (Gp62/2 Plts1MC38 Ctrl or Lgals3 KO TC), or with 10 mM ATPgS, alone or in combination with 20 U/mL apyrase, for 8 hours. Representative
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metastasis.73-75 However, in sharp contrast, Hayashi et al76 pro-
posed a metastasis-suppressing function of galectin-3, based
on the observation that low expression of galectin-3 is associ-
ated with high expression of b3 integrin on the surface of
B16F10 cells, and enhances their metastatic potential by facil-
itating the interaction with fibrinogen and platelets. On the other
hand, in that study, the overexpression of galectin-3 resulted in
the downregulation of b3 integrin and consequently reduced
the metastatic potential of the cells.76 Contrary to those results,
we found that expression levels of galectin-3 had no influence on
the expression of b3 integrin in our cancer cells, demonstrating
that the mechanism reported for B16F10 cells is not of general
relevance (supplemental Figure 10). Furthermore, we used
several cancer cell types, covering a spectrum of differentiation
Figure 5 (continued) immunofluorescence images of ECs with an anti-VE-cadherin antibody (red). Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI; blue). The bar
represents 10 mm. (H-I) MC38 and AT-3 ctrl or Lgals3 KO tumor cells were seeded on endothelial cells (ECs), and tumor cell transmigration was determined in the absence or
























































































































Figure 6. GPVI–galectin-3 interaction promotes tumor cell extravasation and subsequent metastasis. (A,C) Representative fluorescence microscopy images of lung
sections ofWT, Gp62/2 (A) and Syk1/1 and Syk2/2 (C) mice 6 hours after IV injection of MC38-CFSE cells (green). Lung vessels were stained for endoglin (CD105, red). Asterisks
indicate lung alveoli. The bar represents 10mm. (B-D) The bar graphs show the percentage of intravascular and extravascularMC38-CFSE cells in lungs ofWT,Gp62/2, Syk1/1 and
Syk2/2mice; n5 4mice per group; *P, .05, by Fisher’s exact test. (E-F) MC38 and AT-3 tumor cells were injected subcutaneously (E) or directly into the tail vein (F) of Syk1/1 and
Syk2/2 mice. Spontaneous and experimental lung metastasis were determined at 30 and 15 days after injection, respectively. (E) Quantification showing primary tumor volume
(left) and number of metastases (right). (F) Metastases in lungs of Syk1/1 and Syk2/2 mice. Data are presented as the mean6 standard deviation (SD); n5 5 mice per group;
*P , .05; **P , .01, by Mann-Whitney test.
















































































































































Figure 7. Pharmacological blockade of GPVI inhibits tumor metastasis. (A-B) C57BL/6 or BALB/c1WTmice were injected IV with JAQ1 F(abʹ)2 or an irrelevant control F(abʹ)2
antibody, together with the indicated syngeneic tumor cells. (A) MC38 and AT-3 tumor cells are syngenic to a C57BL/6 background and 4T1 tumor cells to a BALB/c1 (B)
background, respectively. (C) C57BL/6 mice were injected with MC38 tumor cells, followed after 7 days by injection with JAQ1 F(abʹ)2 or an irrelevant control F(abʹ)2 antibody.
Number of experimental lung metastases (A,C) in MC38-, AT-3 (A)-, or 4T1 (B)-injected WT mice was determined 15 days after injection. Data are presented as the mean 6
standard deviation (SD); n 5 5 (A-C) and n 5 6 (B) mice per group. **P , .01; ***P , .001, by unpaired Student t test. (D) Proposed model of the role of platelet GPVI in tumor
metastasis. Tumor cells transit from the primary tumor via the blood to form metastases in distant organs. During this process, tumor cells encounter several environmental
changes and stimuli, which profoundly impact their metastatic potential. Following entry of tumor cells into the bloodstream, platelet GPVI favors platelet recruitment to
circulating tumor cells through its interaction with galectin-3 on the tumor cell surface. Once a stable interaction is established, platelets become activated and can protect
tumor cells from hemodynamic shear stress and the host immune system and can favor efficient tumor cell extravasation and subsequent metastasis. The function-blocking
anti-GPVI antibody JAQ1 F(Ab’)2 reduces metastasis by preventing platelet–tumor cell cross talk.
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and metastatic propensities77-83 and clearly showed that in-
hibition of platelet GPVI or tumor cell–derived galectin-3 de-
creased platelet–tumor cell interaction and metastasis. Our
findings also strongly support the clinical observations in humans
that increased galectin-3 levels in solid tumors, including mel-
anoma, colon, and breast carcinoma, correlate with a poor
prognosis and shortened survival and are associated with an
increased number of metastases in the lung and liver.63,84-87 A
possible pathogenic role of GPVI–galectin-3 interaction in hu-
man cancer remains to be demonstrated, but we clearly showed
that human cancer cells also interact with human platelets
through GPVI. Furthermore, in preliminary studies, we found
increased levels of soluble GPVI, indicative of intravascular
GPVI–ITAM activation, in the plasma of patients with advanced
stages of colorectal and breast cancers (supplemental Tables 2
and 4), which correlated positively with cancer stage in these
small cohorts (supplemental Figure 11). Whether GPVI shedding
from the platelet surface was induced by galectin-3 or other
ligands in these patients remains to be addressed in future
studies.
Previously, it has been shown that, under inflammatory condi-
tions, GPVI may also enhance vascular permeability by medi-
ating adhesion of platelets to the inflamed microvasculature.88,89
In contrast, we found that GPVI deficiency did not alter
platelet–endothelial cell interactions in our cancer model (sup-
plemental Figure 12), suggesting that enhanced vascular
permeability during tumor metastasis is a consequence of
GPVI-mediated degranulation in response to galectin-3.
Platelets are the first cells to interact with tumor cells in the
bloodstream, which is followed by the progressive recruitment
of neutrophils to generate a metastatic niche.6,90-92 Recently, we
showed that inhibition of GPVI function could induce intra-
tumoral hemorrhages, observed in the neutrophil-rich area of
the primary tumor.39 Interestingly, galectin-3 deficiency, neither
in tumor cells nor in tumor microenvironment, resulted in
intratumoral hemorrhages, and GPVI deficiency did not induce
hemorrhages in secondary tumors or metastases (supplemental
Figure 13). However, neutrophil depletion in WT mice reduced
tumor metastasis, which was further reduced in GPVI-deficient
mice (supplemental Figure 14), suggesting that the metastasis-
enhancing effect of neutrophils is not dependent on GPVI
function. Although galectin-3 is expressed in neutrophils,
galectin-3 deficiency in host cells (Lgals32/2 mice) did not in-
fluence metastasis of MC38 and AT-3 tumor cells.
GPVI is exclusively expressed in the megacaryocyte/platelet
lineage, largely excluding the risk of side effects of GPVI-
blocking agents on other cell types. Consistently, the injection
of JAQ1 F(abʹ)2 antibody into Gp62/2 mice did not induce any
further decrease in tumor metastasis, confirming the specificity
of the anti-GPVI treatment (supplemental Figure 15). Further-
more, we provide the first in vivo evidence that GPVI blockade
prevents platelet/tumor cell interactions and inhibits lung me-
tastasis in mice. This opens a new perspective to develop a
therapeutic strategy aiming to target GPVI, thereby inhibiting
tumor metastasis in cancer patients. In line with previous reports,
JAQ1 injection did not induce severe thrombocytopenia, and
the resultant GPVI deficiency had no major effect on normal
hemostasis.32,93 Similarly, GPVI deficiency in humans causes a
relatively mild bleeding diathesis94; therefore, it is tempting to
speculate that targeting of GPVI in patients should be possible
without inducing major bleeding complications.
A randomized cardiovascular prevention trial has provided ev-
idence of an antimetastatic effect of low, platelet-inhibiting
doses of ASA in patients.95 In our AT-3 cancer model, ASA
alone strongly inhibited tumor metastasis, which was further de-
creased by using combined therapy with ASA and JAQ1 F(abʹ)2
(supplemental Figure 16). Consistently, Lucotti et al96 recently
showed that ASA treatment could decrease platelet aggregation
on tumor cells, endothelial cell activation, tumor cell–endothelial
cell interactions, and recruitment of metastasis-promoting
monocytes to premetastatic niches. Although our results show
that GPVI blockade inhibits the early phase of cancer metastasis
(ie, the time frame in which platelet–tumor cell interactions
occur6), ASA treatment seemed to act on both early and late
phases of metastasis. Whether such dual therapy could be
applied to cancer patients will require further investigation.
However, a major drawback of ASA and other currently used
antiplatelet drugs is their strong effects on hemostasis,4,95,97-100
which limits their use in clinical settings. Of note, it has been
shown that anti-GPVI therapy may result in markedly prolonged
bleeding times when given in combination with ASA.101
Revacept, a competitive GPVI inhibitor comprising the GPVI
ectodomain fused to human IgG Fc, has been successfully
evaluated in clinical trial phase I.102-104 Previously, Dovizio
et al105 showed that Revacept has inhibitory effects on
platelet-mediated epithelial–mesenchymal transition and
cyclooxygenase-2 synthesis in vitro in HT29 cells. We evaluated
the antimetastatic potential of a soluble dimeric mouse GPVI-Fc
fusion protein,43 an agent similar to Revacept. Soluble GPVI-Fc
dimer treatment decreased platelet–tumor cell interactions and
metastasis of MC38 and AT-3 cells to a similar extent as JAQ1
F(abʹ)2 treatment, but we did not find any changes in the ex-
pression profile of epithelial and mesenchymal gene markers,
upon treatment with either GPVI-Fc or JAQ1 F(abʹ)2 (supple-
mental Figure 17).
To summarize, our study demonstrates a major contribution of
GPVI to platelet interaction with colon and breast cancer cells
through the binding of galectin-3. This interaction triggers
platelet activation and subsequent extravasation of tumor
cells. Therefore, targeting of GPVI in humans may represent
a novel antimetastatic strategy without significantly affecting
hemostasis.
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